AbCellera Biologics (ABCL) Cash from Financing Activities (2020 - 2026)

AbCellera Biologics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $7.2 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 20.47% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.3 million (down 3.8% YoY) and the FY2025 annual result came in at $14.1 million, up 10.28% from the prior year.
• Cash from Financing Activities was $7.2 million for Q1 2026 at AbCellera Biologics, up from $4.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $7.4 million in Q3 2025 and bottomed at -$3.4 million in Q2 2025.
• A 5-year average of $2.5 million and a median of $2.8 million in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 34994.74% — and 2025, when it slumped 227.31%.
• AbCellera Biologics' Cash from Financing Activities stood at $349000.0 in 2022, then jumped by 978.8% to $3.8 million in 2023, then climbed by 10.01% to $4.1 million in 2024, then slipped by 0.65% to $4.1 million in 2025, then jumped by 74.78% to $7.2 million in 2026.
• Business Quant data shows ABCL's Cash from Financing Activities at $7.2 million in Q1 2026, $4.1 million in Q4 2025, and $7.4 million in Q3 2025.